• SYNGR3 Drives α-Synuclein Aggregation in Parkinson’s Disease

  2026-06-29

  This study identifies synaptogyrin-3 (SYNGR3) as a novel accelerator of α-synuclein aggregation and neurodegeneration in Parkinson’s disease models. By elucidating SYNGR3’s direct interaction with α-synuclein and its impact on mitochondrial function and synaptic integrity, the findings suggest a new mechanistic target for therapeutic intervention and experimental modeling.

• Risedronate Sodium: Advanced FPP Synthase Inhibitor Workflow

  2026-06-29

  Risedronate Sodium uniquely bridges osteoporosis and pulmonary research, offering both osteoclast inhibition and macrophage-targeted apoptosis. This guide details experimental workflows, nanoformulation strategies, and troubleshooting tips to maximize its translational impact.

• Caspase-3 Fluorometric Assay Kit: Precision in Apoptosis Ass

  2026-06-28

  Unlock rapid, quantitative apoptosis analysis with the Caspase-3 Fluorometric Assay Kit from APExBIO. This guide details experimental workflows, protocol refinements, and real-world troubleshooting strategies for advanced caspase signaling pathway studies.

• High-Throughput Surrogate Barrier Model Advances BBB Predict

  2026-06-27

  A recent study presents a robust in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, enabling high-throughput prediction of CNS drug permeability. By correcting for lysosomal trapping and validating predictive capacity across 41 compounds, this approach offers a scalable, cost-effective tool for early-stage neurological drug discovery.

• SCH772984 HCl: Advanced ERK1/2 Inhibitor Workflows in Cancer

  2026-06-26

  SCH772984 HCl, a potent ERK1/2 inhibitor from APExBIO, enables precision dissection of MAPK signaling in both oncology and cardiomyocyte translation studies. This guide delivers actionable protocols, troubleshooting tips, and workflow insights drawn from the latest research, supporting innovation in resistance modeling and spatial control of protein synthesis.

• Neuromedin S (rat): Technical Guidance for GPCR Assays

  2026-06-26

  Neuromedin S (rat) provides a chemically defined, endogenous peptide agonist for selective neuromedin U receptor activation in rat GPCR/G protein signaling research. It is best suited for controlled in vitro or ex vivo studies of energy homeostasis, stress response, and circadian rhythm regulation. This product is not intended for diagnostic, therapeutic, or cross-species applications.

• Simultaneous Detection of Amatoxins and Phallotoxins in Mush

  2026-06-25

  This study introduces a computationally guided strategy to develop monoclonal antibodies that enable highly sensitive and simultaneous detection of lethal amatoxins and phallotoxins in mushrooms. The resulting dual-target fluorescent immunochromatographic assay offers a rapid, specific, and practical tool for mushroom toxin analysis, with significant implications for both food safety and public health.

• Z-WEHD-FMK: Redefining Caspase Inhibition in Translational R

  2026-06-25

  Explore how Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) advances mechanistic insight and strategic workflow design in inflammation, apoptosis, and infectious disease research. Drawing on new evidence for caspase-1’s role in pyroptosis and tumorigenesis, this article bridges molecular understanding with practical guidance for translational investigators, highlighting protocol nuances, experimental pitfalls, and future opportunities.

• PDK4-IN-1 Hydrochloride: Precision PDK4 Inhibition for Metab

  2026-06-24

  PDK4-IN-1 hydrochloride empowers metabolic research with nanomolar-selective PDK4 inhibition, enabling robust PDH activation and mitochondrial energy modulation. This guide details experimental workflows, troubleshooting insights, and advanced use-cases that distinguish this compound for both in vitro and in vivo studies.

• BMX-IN-1: Precision BMX Kinase Inhibitor Workflows & Trouble

  2026-06-23

  BMX-IN-1, a highly selective BMX kinase inhibitor from APExBIO, empowers researchers to dissect signaling in both cancer and infectious disease models. This guide delivers actionable protocols, highlights cutting-edge findings on BMX’s role in host-pathogen interactions, and provides expert troubleshooting tips for reliable experimental outcomes.

• Targeted mRNA Nanoparticles Restore BBB After Ischemic Strok

  2026-06-23

  This study pioneers a lipid nanoparticle system for targeted mRNA delivery to modulate microglial polarization, thereby restoring blood-brain barrier (BBB) integrity after ischemic stroke. The approach demonstrates extended neuroprotection and reduced neuroinflammation, offering a platform for precise poststroke interventions.

• Olsalazine Sodium: Applied Workflows for Inflammation & Canc

  2026-06-22

  Olsalazine Sodium, a potent mesalamine dimer, is redefining experimental workflows in inflammation and colorectal cancer models. This guide distills protocol enhancements, troubleshooting strategies, and actionable insights from recent studies, empowering researchers to harness its anti-inflammatory and tumor-modulating properties with confidence.

• Dantrolene Sodium Salt: Precise Ryanodine Receptor Antagonis

  2026-06-22

  Dantrolene sodium salt is a high-purity ryanodine receptor antagonist that enables precise modulation of intracellular calcium release in research models. Its nanomolar potency and calmodulin-dependent inhibition underlie its utility in disease modeling, genome editing, and synthetic lethality studies. APExBIO supplies validated, workflow-ready dantrolene sodium salt (SKU B6329) for reproducible, high-fidelity results.

• Sulfachloropyridazine in Research: Protocols and Microbiome

  2026-06-21

  Sulfachloropyridazine is a versatile sulfonamide antibacterial agent pivotal for dissecting microbial resistance, enzyme inhibition, and gut microbiota modulation. By integrating advanced protocols and troubleshooting insight, researchers can harness its full potential in antimicrobial susceptibility testing, enzyme assays, and in vivo infection models.

• YM 58483 (BTP2): Selective SOCE Blocker for Immune and Fibro

  2026-06-20

  YM 58483 (BTP2) is a potent, selective inhibitor of store-operated Ca2+ entry (SOCE), targeting CRAC and TRP channels to suppress T cell activation and fibrogenesis. Its use enables precise dissection of calcium-dependent signaling in immune and radiation-induced fibrosis models. Recent studies validate YM 58483's efficacy in mitigating early-stage salivary gland fibrosis by blocking the ORAI2/JNK/NFAT1 axis.

16792 records 1/1120 page Next 12345 下5页 Last page